Specific biomarkers have been identified that could help assess the likelihood and severity of the recurrence of malignant glioma, a highly aggressive form of brain cancer, according to a study.
The Intraoperative MRI (iMRI) suite is a brand new tool at Dixie Regional Medical Center that’s changing the way brain surgery is performed. In this area, a metal door is all that separates brain surgery from MRI.
There have been promising results a drug approved for the treatment of pinworm showed when used in treating brain cancer. Encouraged by those results, another team of researchers turned to determining whether mesothelioma cells would also respond. Early study results show another parasitic drug could “effectively impair both mesothelioma cell growth and migration.”
Researchers have found an Achilles' heel for the most common form of malignant child brain tumors. By combining two kinds of medicines, it is possible to simultaneously attack the cancer cell’s division and its reinforcement system, which is necessary in order for treatment to be sufficiently effective.
The Brain Tumor Funders’ Collaborative works to identify potential therapies for patients with primary human brain tumors, with the goal of increasing progression-free patient survival and improving quality of life for patients affected by a primary brain tumor.
In a documentary titled: “Benefits for Humanity: From Space to Surgery” it explores the space robotics origins of Synaptive Medical’s robotic digital microscopes, Modus V and BrightMatter Drive. The video examines how technology has been adapted to healthcare and is now benefiting patients with brain cancer and spine diseases.
The addition of tumor-treating fields to maintenance temozolomide therapy extended survival among a cohort of patients with glioblastoma, according to results of a randomized phase 3 study. The regimen — in which a device attached to a patient’s scalp delivers continual doses of low-intensity electric fields — did not negatively affect patients’ quality of life, results showed.
Around the time the ketogenic diet was being developed, the work of a German biochemist named Otto Warburg began to uncover a potential application for this diet in the treatment of cancer. Warburg observed that cancer cells typically derive energy from different sources than healthy cells.
A single gene has been linked to an aggressive form of brain cancer, potentially paving the way for new therapies to treat the disease, according to research.
A new integrated 'omics analysis suggests that the transcription factor FOXM1 can act as a meningioma driver, prompting proliferation, progression, and relatively poor outcomes in individuals with the disease, a primary central nervous system tumor that forms in meninges tissue surrounding the brain and spinal cord.
Michigan State University scientists are testing a promising drug that may stop a gene associated with obesity from triggering breast and lung cancer, as well as prevent these cancers from growing.
The surgery looked like any other operation to remove a tumor. When doctors turned off the lights, however, parts of the patient’s chest started to glow. A spot over his heart shined purplish-pink. Another spot lit up in his lung.
Cholesterol may be required for medulloblastoma tumors to grow, study results showed. This finding suggests statins may be an effective therapy, according to researchers in the laboratory of Zeng-jie Yang, MD, PhD, associate professor in the cancer biology program at Fox Chase Cancer Center.
New ultrahigh field 7 Tesla Magnetic Resonance Imaging scanner — which uses a more powerful magnet to produce clearer images than standard scanners.
Young mice that received molecularly targeted therapies used to treat brain cancer in human patients sustained cognitive and behavioral deficits, but the deficits were largely reversible through environmental stimulation and physical exercise.
A new research effort by an international team of scientists reveals that machine-learning algorithms can be a powerful tool for medicine. The group managed to create and train an AI to successfully identify different types of brain tumors with impressive accuracy.
An international team of researchers has used methylation fingerprinting data as input to a machine-learning algorithm to identify different types of brain tumors. The team describes studying DNA methylation fingerprinting to create a system that is able to identify central nervous system (CNS) tumors and report on its accuracy.
While there are many types of radiation that are successful for cancer treatment, the benefit of using proton beams is that they target the treatment area without hitting other healthy areas, said Dr. Mitchell Machtay, chair of the UH department of radiation oncology.
There is some encouraging news in the battle against the deadliest form of brain cancer. It's an experimental drug that gets right to the tumor.
A new study by investigators finds that some types of glioblastoma tumors may be able to shed extracellular vesicles (EVs) - small packages of biomaterial - that can help to suppress the body's ability to mount an immune response against the tumor.
Called Tumor Treating Fields, the therapy was pioneered less than two decades ago by Israeli scientist Yoram Palti, who showed that when alternating electric fields are delivered at specific frequencies, they can disrupt the division of cancer cells and cause their death.
Investigators are seeking to determine whether the combination of eflornithine (alphadifluoromethylornithine) with lomustine can improve survival for patients with recurrent anaplastic astrocytoma (AA).
New research described how deep convolutional neural networks (CNNs) may improve MRI brain tumor segmentation. Computer engineering researchers proposed a high-capacity deep convolutional neural networks (DCNN) for the study.
Surgery, radiation and chemotherapy just don’t cut it against glioblastoma, a type of aggressive brain tumor with a dismal five-year survival rate. Survival is highest in younger people, at 19% for those aged 20 to 44, but it drops sharply with age, bottoming out at 5% for patients over 55. That’s why Gianpietro Dotti is working on an immunotherapy for glioblastoma.
Genetically engineered cancer-killing T-cells can hunt and attack brain tumors that display a new molecular target that is highly prevalent on brain cancer cells, report researchers.
Using tumor genome sequencing, researcher identified the first potential targeted drug to treat chordoid gliomas, a rare type of brain cancer that develops within the third ventricle, a fluid-filled pocket that helps cushion the brain.
Re-engineering a common cold virus to attack the deadliest kind of brain tumor extended the survival of patients whose tumor returned after various treatments, including surgery, a Phase 1 clinical trial shows. While patients with glioblastoma usually live a median of six months, half were still alive at 9/12 months after receiving the re-engineered virus. And 20 percent lived for three years or longer.
Nativis, a Seattle-based company developing a device that uses low-frequency radio energy waves to treat cancer and other diseases, announced Tuesday that its Voyager device is being considered for fast-track approval by the U.S. Food and Drug Administration.
Scientists just figured out how to shrink tumors using robots built from DNA strands. Their new technique was tested on breast, skin, ovary and lung cancers in both mice and pigs. It's a win because the robots can find and attack cancer cells, starving them of fresh blood supply, without hurting the rest of the body.
The collaboration of a chemical engineer who has done extensive computer modeling of biological and engineering systems a neurobiologist whose expertise is in cell motion and behavior in the brain, has produced a new and freely available computer program that predicts cancer cell motion and spread with high accuracy.
Researchers at Dartmouth's Norris Cotton Cancer Center, led by Damian A. Almiron Bonnin, MD-Ph.D. candidate of the Mark Israel laboratory, are devising strategies to prevent brain tumors from becoming resistant to anti-tumor drug treatment.
At age 7, Bella is seeing better results from a precise radiation called “proton beam therapy.”
“This type of radiation can go to the tumor, stop and then come back out,” said Josh, “whereas traditional radiation would pass through and then kinda bounce around.”
A common cold virus engineered to attack the most common and deadly of brain tumors allowed 20% of patients with recurrent glioblastoma to live for 3 years or longer, researchers from The University of Texas MD Anderson Cancer Center report on a phase I clinical trial in the Journal of Clinical Oncology.
Immune checkpoint inhibitors targeting the PD-1 pathway could be a promising approach in treating certain children with an aggressive form of brain cancer known as supratentorial pediatric ependymoma, researchers suggest. Pediatric ependymoma (EPN) is the third most common cancer of the central nervous system.
An undergraduate biochemistry student at Clemson University, approached his professor about wanting to start research on “some human stuff” in the spring of 2016, he didn’t imagine it would lead to the discovery of 22 genes that are implicated in glioblastoma, the most aggressive type of brain cancer.
Scientists have successfully uncovered a therapeutic approach that targets aggressive brain cancer stem cells and could lead to improved patient survival.
Researchers at Dartmouth's Norris Cotton Cancer Center, led by Damian A. Almiron Bonnin, MD-PhD candidate of the Mark Israel laboratory, are devising strategies to target glioma stem cells which could significantly improve patient survival.
Immunotherapy continues to prove its mettle in the fight against various forms adult cancers ranging from melanoma to lung cancer, to kidney cancer, and more. For instance, drugs that target immune checkpoint pathways, such as programmed cell death protein 1 (PD-1), help remove the genetic blindfold that cancer uses to hide from the immune system.
NBTS) today announced the launch of a new patient and care-partner education and preparedness effort. The new initiative will provide those going through the brain tumor medical experience with the information, tools, and guidance needed to play a more active role in their treatment planning and decisions.
Scientists have created a hair-thin implant that can drip medications deep into the brain by remote control and with pinpoint precision. Tested only in animals so far, if the device pans out it could mark a new approach to treating brain diseases — potentially reducing side effects by targeting only the hard-to-reach circuits that need care.
A diagnosis of the brain cancer glioblastoma carries a dismal prognosis. Now a team led by Massachusetts General Hospital investigators has found that adding the chemotherapy drug hydroxyurea to the current chemotherapy protocol for glioblastoma significantly increased survival in animal models.
The prognosis for all children diagnosed with an aggressive brain tumor known as DIPG and similar tumors has been mostly the same: dismal. But a small subset of patients with these tumors that bear mutations in a gene in the basic packaging of DNA may have better outcomes than others, suggests new research.
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.
A drug that targets cancer cells’ ability to self destruct was recently cleared to be used in clinical trials for brain cancer patients. Patients with glioblastoma multiforme, an aggressive cancer of the brain, will be using this drug, PAC-1, with temozolomide, a traditional chemotherapy drug used as the standard form of treatment for brain tumors.
A unique clinical trial at the hospital and Georgia Cancer Center at Augusta University where Kaiden was one of the first kids with his kind of cancer to receive a homegrown therapy first discovered at Medical College of Georgia. The therapy is a drug called Indoximod that blocks an enzyme called indoleamine 2,3-dioxygenase or IDO for short.
Hyperspectral imaging, where data is captured over several contiguous narrow spectral bands, rather than the three distinct color bands of a conventional camera, is an attractive technique in medical treatment and diagnosis thanks to its non-contact and minimally invasive nature.
Biological clocks throughout the body play a major role in human health and performance, from sleep and energy use to how food is metabolized and even stroke severity. Now, Texas A&M University researchers found that circadian rhythms could hold the key to novel therapies for glioblastoma, the most prevalent type of brain cancer in adults—and one with a grim prognosis.
BXQ-350 combines a protein which is naturally expressed in humans, with nanobubbles of a fat molecule. This combination creates a treatment agent that has the ability to selectively target cancerous tumor cells and then kill them, largely sparing the surrounding healthy tissues.
A 27-year-old man has made a remarkable recovery from a first-of-its-kind brain tumor operation in Minnesota. Peter Carvalho underwent a three-hour operation less than a month ago in which a laser was used to heat up and destroy a brain tumor, which had caused depression and changes in his personality.
A little known pharmaceutical company in Florida has found itself in the eye of a storm following disclosures it raised the price of an old drug used to fight brain tumors by 1,400%, from US$50 a pill to more than $700. NextSource Biotechnology in 2013 bought the license for the drug Lomustine from Bristol-Myers Squibb.
Diffusion tensor imaging (DTI) may indicate prognosis among patients with brain metastases and the likelihood of their response to immunotherapy, according to a study published in Cancer Research.
It was announced today the initiation of a phase 1 study. The first patient has been treated in this open-label dose-escalation study to determine the safety and tolerability of the oral formulation of Basilea's novel anticancer drug candidate BAL101553 in combination with standard radiation in patients with newly-diagnosed glioblastoma.
The UW Health brain tumor program in Madison, Wisconsin, consists of a multidisciplinary team of neurosurgeons, radiation oncologists, medical neuro-oncologists, neuroradiologists, neuropathologists, neuro-otologists, pediatric neurologists, pediatric neuro-oncologists and pediatric neurosurgeons.
Man's best friend may help scientists learn more about a deadly brain cancer in people. Both dogs and humans can develop glioblastoma. Half of people diagnosed with this type of brain cancer live fewer than 14 months, even after treatment with surgery, radiation and chemotherapy.
A new study demonstrates that adding electric field therapy to chemotherapy can improve survival for those with glioblastoma, which is an aggressive brain cancer with few effective treatment options.
A device attached to a patient’s scalp that delivers a continuous dose of low-intensity electric fields can improve survival and slow the growth of a deadly brain tumor, a new clinical trial suggests. The new treatment for glioblastoma uses alternating electric currents called tumor-treating fields (TTFields), delivered through an array of insulated electrodes affixed to a patient’s shaved scalp.
A common medical test may help predict how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy utilizing a novel MRI technique called Diffusion Tensor Imaging (DTI), which has the potential to remove the need for patients to undergo costly and dangerous biopsies.
According to research lead by the University of California San Francisco (UCSF), children with a deadly form of brain cancer might benefit from a new treatment that aims to direct an immune response against a mutated protein found exclusively on cancer cells.
The novel oncolytic virus Toca 511 (vocimagene amiretrorepvec) and Toca FC (extended-release 5-fluorocytosine [5-FC]) induced durable responses in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA).
Doctors use a bioengineered protein that leaves healthy cells alone. It is called MDNA 55. "It can bind directly to tumor cells and bring in a payload, which is like a Trojan horse that acts directly on tumor cells and causes the tumor cells to undergo programmed cell death," said Achal Singh Achrol.
The U.S. Food and Drug Administration (FDA) has granted full approval for Genentech's Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease).
An autopsy revealed something unexpected: Her bone tumors had melted away, leaving only a few cancer cells in her marrow.
The focus of the study, published online Dec. 4 in the Journal of Experimental Medicine, is diffuse intrinsic pontine glioma (DIPG), an aggressive pediatric brain cancer. DIPG is rare — estimates suggest that about 300 new cases occur in the United States each year — but almost always fatal.
Children with an extremely deadly form of brain cancer might benefit from a new treatment that aims to direct an immune response against an abnormally shaped protein found exclusively on cancer cells, according to a new study led by UC San Francisco researchers.
Glioblastoma is a type of very aggressive brain tumor. It's the same kind of tumor diagnosed in U.S. Sen. John Mccain.
About 12 to 15 percent of people with brain tumors have glioblastomas.
Previously, the authors of the study have shown that an experimental drug that inhibits polo-like kinase 4 (PLK4) stopped pediatric brain tumor growth in vitro. Now, they have demonstrated its success in an animal model - the drug shrank the tumor and increased survival.
A Boston biotech with a unique approach to treating an aggressive brain tumor, Ziopharm Oncology reported this weekend that its combination of experimental drugs has helped 15 patients survive about twice as long as they would have otherwise in an early-stage trial.
UC San Diego Health has expanded its treatment of rare brain tumors by launching a specialized program in the diagnosis and treatment of acoustic neuromas and complex skull base tumors.
The term “skull base” refers to the gap between the bottom of the brain and the part of the skull that is directly below it. Within the skull base are the blood vessels that supply the brain with nutrients and oxygen, as well as nerves that are critical to functions such as vision, smell, hearing, facial movement and breathing.
The newly-appointed head of the University of Minnesota Medical School’s neurosurgery department has unveiled encouraging early results from a research collaboration with a California biotech company seeking to treat aggressive and deadly brain cancer tumors.
A particularly aggressive form of pediatric cancer can be spotted reliably by the genetic fragments it leaves behind in children’s biofluids, opening the door to non-surgical biopsies and providing a way to gauge whether such tumors respond to treatment.
St. Jude Children's Research Hospital scientists have discovered a promising target for precision medicines to block a mechanism that drives several cancers, including about 30 percent of cases of the brain tumor called medulloblastoma.
A team from the Northwestern University Feinberg School of Medicine and the Translational Genomics Research Institute (TGen) have turned to ultra-low dosages of arsenic as a potential treatment against glioblastoma multiforme (GBM)—the most common and aggressive type of deadly brain tumor.
Bentley, a canine patient of Bush Veterinary Neurology Service (BVNS), has had a remarkable response to treatment of a glioma brain tumor. The treatment was performed through a clinical trial funded by the National Institutes of Health.
Doctors are now using a virus from a disease that's been largely eradicated to fight brain tumors.
The polio virus is the latest weapon in the fight against cancer.
Brain Tumor Research-funded Centre of Excellence, has secured funding from the Brain Research Trust, which will help to expose novel molecules and their modes of action responsible for the initiation and growth of the disease.
A team of researchers led by the University of Texas at Austin has developed a new, fully automatic method that combines biophysical models of tumor growth with machine learning algorithms to automatically identify brain tumors.
In a Yale School of Medicine laboratory, Pediatric Oncologist Dr. Juan Vasquez, is working hard at coming up with a vaccine to fight off brain tumors in children.
Study found that the drug combination tested in mice disrupts and exploits glucose intake, essentially cutting off the tumor's nutrients and energy supply. This treatment then stimulates cell death pathways which control the cancer cells' fate and prevents the glioblastoma from getting bigger.
A research group from the University of Texas at Austin’s Texas Advanced Computing Center presented results of a new, fully automatic method combining biophysical models of tumor growth with machine learning algorithms for the analysis of Magnetic Resonance (MR) imaging data of glioma patients.
As a neurosurgeon at Seattle Children’s Hospital, Dr. Amy Lee imagines a day when she’s removing an invasive brain tumor from a child while looking at a screen shining brilliant green, showing her precisely where the tumor ends and the healthy brain tissue begins.
The absence of a signaling molecule produced by the brain’s nerve cells stops the growth of certain brain tumors, according to a recent study by a group of researchers at Stanford’s School of Medicine.
New research out of MIT has made great strides into discovering the fundamental mechanisms behind this form of brain tumor. They have now found the reasons behind why glioblastomas grow so aggressively.
New research brings fresh hope of a new treatment for patients with glioblastoma, after identifying a way to halt the growth of this life-threatening brain tumor. Scientists have identified the mechanism by which a specific protein called PRMT5 drives the growth of glioblastoma tumors.
The researchers also identified a genetic marker that could be used to predict which patients would most likely benefit from this type of treatment. Glioblastoma is usually treated with radiation and the chemotherapy drug temozolamide, which may extend patients' lifespans but in most cases do not offer a cure.
MGMT promoter methylation status -- information gathered at a DNA-level -- can help predict overall survival for patients with a rare form of brain cancer known as anaplastic astrocytoma, according to a new analysis
The brain cancer diagnosis of glioblastoma has been in the headlines in the wake of Senator John McCain’s recent diagnosis the he describes as ‘very poor”. In this story we will go over the very basics of the 4 grades of brain tumors and the treatments available for them.
•Long-term results from a Phase 3 clinical trial, EF-14, assessing the addition of Novocure's (NVCR -0.7%) Optune to temozolomide in patients with newly diagnosed glioblastoma showed extended survival and improved quality of life.
Finding a cure is tough, but one promising trial at the UT Health Cancer Center is giving one local family hope.
New research conducted in mice provides evidence that highly lethal brain tumors, called high-grade gliomas, stop growing when deprived of a specific molecule naturally produced when brain cells fire.
Mayo Clinic Phoenix is using MRI scans and other pathology to create mathematical equations to tell them what a brain tumor is likely to do. Tumors, in a way, while they may seem to be unpredictable, actually follow a pattern
The largest genomic profiling study ever conducted into glioma brain tumors in children has identified genetic alterations in 96% of cases. As reported in The Oncologist, this genetic information could help to identify the most effective treatments for specific cases of glioma
The discovery of a mechanism by which normal brain cells regulate the expression of the NFIA gene, which is important for both normal brain development and brain tumor growth, might one day help improve therapies to treat brain tumors.
A study reports that the same biological qualities that let Zika do its devastating neurological fetal damage, can also destroy the stem cells of glioblastoma, the most common type of brain tumors.
The discovery of a mechanism by which normal brain cells regulate the expression of the NFIA gene, which is important for both normal brain development and brain tumor growth, might one day help improve therapies to treat brain tumors.
Cancer metastases to the brain are a major healthcare burden. For single metastases, surgical removal of the tumor followed by whole brain radiotherapy (WBRT) is the standard of care and has been shown to improve survival compared with WBRT alone. However, it may also decrease cognitive function.
A research team found that the Zika virus may selectively kill brain tumor cells while not harming normal brain cells...in a laboratory. The results are promising.
Researchers have discovered that the Zika virus can kill tumor cells from glioblastoma cancers. Here’s how it does that.
A study conducted by a researcher at São Paulo State University in Brazil, with support from the São Paulo Research Foundation (FAPESP), explores the mechanisms that make astrocytomas so aggressive and seeks ways to customize treatment to patient needs.
An experimental imaging tool that uses a targeted fluorescent dye successfully lit up the benign brain tumors of patients during removal surgery, allowing surgeons to identify tumor tissue shows.
Researchers at the Yale School of Medicine have used the CRISPR/Cas9 system — which allows researchers to alter the DNA sequence at specific points — to create a new and advanced mouse model for glioblastoma.
Researchers in Florida are using immunotherapy against two of the toughest medical problems: glioblastoma brain tumors and infections from sepsis and septic shock. Both conditions are deadly and fast-moving.
3D printed tumor models can help doctors and surgeons to get a better look at and understanding of the masses that they’re going to be treating or removing from a patient’s body, and they can also help patients to understand their own conditions.
Doctors Robert Fenstermaker and Michael Ciesielski have spent the last 20 years at Roswell Park, looking for ways to combat brain cancers.
"About 12 years ago, we started looking at a protein target called Survivin. It's expressed on tumor cells, it looked interesting, that this might be something we'd want to develop a vaccine to,” Ciesielski said.
The surgeons primarily created a computer model of the tumor to see where it is located and which parts of the brain it aligns to. The model became a navigation map for a computer system and a doctor.
There has been a lot of excitement recently surrounding the WP1122 technology and its potential to become a new approach for treating brain tumors.
A recently developed method of diagnosing 13 kinds of cancer from a single drop of blood can lead to early detection of the disease. The relatively inexpensive test puts less burden on patients, but it still needs further improvement in accuracy.
A Buffalo researcher and his research team have a potentially life saving therapy in the palm of their hands. They say they’re so close to getting a cancer fighting therapy on the market.
Neuroscientists have uncovered the genetic basis for why many long-term survivors of childhood cancer develop meningiomas, the most common adult brain tumour, decades after their treatment with cranial radiation.
Doctor trying a new technique called Magnetic Resonance Fingerprinting. It was developed at Case Western Reserve University in Cleveland. They have initial results from 25 children in a study.
In order for a cancer cell to enter the brain, it must first bind to the cells that line the structure separating the blood from the brain, which is called the blood-brain barrier (BBB). Such information about the factors associated with this process may provide a way of preventing the cancer cells binding to the BBB and crossing over into the brain.
Researchers in Roanoke are developing ways to halt the insidious onslaught of the type of brain tumor affecting Arizona Sen. John McCain.
New treatment bought brain tumor patient years of life
In April 2012, Phil enrolled in a clinical trial at M.D. Anderson Cancer Center in Houston. Doctors drilled a hole into his skull and injected his tumor with an altered form of the cold virus called Delta 24, designed to get the virus to consume the brain tumor, and, as viruses do, to make copies of itself that would eat more tumor.
U.S. Senator John McCain is battling glioblastoma. These tumors had been difficult to remove because the cells dig in deep into the brain, and the fingers of the cells extend out centimeters away from the tumor. Doctors couldn’t see them, until recently with the drug Gliolan or 5 ALA, that turns the cancer cells pink has been approved by the FDA.
For patients, like Sen. John McCain (R-Ariz.), who develop aggressive brain cancer, the first-line treatment is almost always radiation and chemotherapy. But if the glioblastoma recurs, and it almost always does, what then?
New research has identified a key mechanism that allows cancerous growths to proliferate, or multiply, in the brain. This has led scientists to develop a new drug that could be used to inhibit malignant cells.
The new treatment, called Intra-Arterial Chemotherapy, or IAC, delivers chemotherapy through the femoral artery in the leg, then through the body, and into the brain, where the chemotherapy is released in blood vessels directly feeding the site of tumor.
The Hippocratic Oath advises doctors to first DO NO HARM … so imagine intentionally using a virus that causes paralysis in hopes of treating the deadliest form of brain cancer.
Researchers have identified a unique metabolic signature associated with epileptic brain tissue that causes seizures. The chemical biomarker can be detected noninvasively using technology based on magnetic resonance imaging.
Patient benefits by a new piece of equipment, a “positioning board” that allows for even more precise targeting of tumors, as part of radiation therapy in the Gainesville-based Northeast Georgia Health System.
Experimental Brain Cancer Therapy Harnesses Stem Cells, Cold Virus
A phase 1 clinical trial is exploring an investigational neural stem cell therapy for the treatment of brain cancer. This approach combines stem cell therapy with a common cold virus and has been observed to target and kill aggressive brain cancer cells, according to a press release from Northwestern Medicine.
Early phase Northwestern Medicine research has demonstrated a potential new therapeutic strategy for treating deadly glioblastoma brain tumors. The strategy involves using lipid polymer-based nanoparticles to deliver molecules to the tumors, where the molecules shut down key cancer drivers called brain tumor-initiating cells (BTICs).
The team has developed cancer-killing viruses that can deliver stem cells via the carotid artery, and applied them to metastatic tumors in the brains of clinically relevant mouse models.
Scientists reveal, for the first time, the role of the cellular prion protein in the development of neurofibromatosis 2 tumors -- with potential impact on other cancers, too
Experimental treatment provides hope against brain tumor
Researchers have developed a new method to screen brain tumor cells and identify potential drug targets missed by traditional methods finding a new drug target in glioblastoma that, when inhibited, significantly extended survival in preclinical mouse models.
New research has identified a specific change in the body’s immune system that may be a predictor of the most common cancerous brain tumors ― gliomas ― five years before an individual develops symptoms.
A therapy based on a discovery there nearly 20 years ago is offering him and others a better quality of life and hope for the future.
Between 8 and 18 percent of people who have cancer also have diabetes. A strong link exists between diabetes and different types of cancer.
There may be new hope in extending the lives of patients with GBM. Researchers from The University of Texas Southwestern Medical Center in Dallas have tested a new approach that has proven to destroy GBM in mice. The study was recently published in Nature Neuroscience.
Immune Cells Deliver Cancer Drugs to the Brain
By harnessing neutrophils, a critical player in the innate immune response, scientists have devised a way to deliver drugs to kill these residual cells, according to a mouse study published today (June 19) in Nature Nanotechnology.
Rethinking the way a tumor creates its blood supply is providing Augusta University researchers with a unique and patented target that could lead to a better way to choking off tumors.
Five Years Before Brain Cancer Diagnosis, Changes Detectable in Blood
Changes in immune activity appear to signal a growing brain tumor five years before symptoms arise. Interactions among proteins that relay information from one immune cell to another are weakened in the blood of brain cancer patients within five years before the cancer is diagnosed,
Research into oleic acid – the primary ingredient in olive oil – has shown how it can help prevent cancer-causing genes from functioning in cells.
There are many advances on the horizon that will change the trajectory of brain cancer treatment, according couple of directors of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute in Boston.
Doctors at Nicklaus Children’s Hospital last month used magnetic-resonance guided ultrasound to treat a 21-year-old student with a brain tumor, essentially using the heat from high-intensity ultrasound waves to destroy the tumor.
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
Brain tumors have unacceptably low survival rates and exceedingly high medical costs, often leaving survivors suffering from lifelong functional deficits. In order to see improved outcomes, brain tumor advocates are targeting the federal government.
Surgeons have used gamma knife technology for years during delicate brain surgeries. It’s not a knife at all, but a focused beam of radiation that carries less risk of damaging nearby tissue. A new version of the knife is extending the therapy to patients who have had very few options, until now.
Scientists in Britain plan to harness the Zika virus to try to kill brain tumor cells in experiments that they say could lead to new ways to fight an aggressive type of cancer. The research will focus on glioblastoma which has a five-year survival rate of barely 5 percent.
Technological advancements mean that more precise, effective treatments are available for a wide variety of cancers.
Tumor suppressor genes, as their name implies, prevent tumors. Their failure can lead to cancer. But a study led by UC San Diego scientists demonstrated that, in one kind of glioblastoma, inhibiting a tumor suppressor gene, called DAXX actually slows down the cancer.
Glioblastoma is an unusually aggressive malignancy with a dismal 5-year survival rate. That's at least in part because these tumors employ several molecular mechanisms that suppress and evade patients' antitumor immune responses.
The research team will grow cells from various brain tumors, adding cannabidiol molecules to only some of them. They will then compare the samples through a cell staining process, which will let them see how many of the cells are dividing and how many are dying.
Having high blood sugar or diabetes is linked to a higher risk of developing most cancers. However, studies have found that brain cancers such as glioma are less common in people with diabetes and high blood sugar. Now, a new study begins to shed light on this surprising link.
There were striking immune responses to the study regimen and very striking survival times for patients with Glioblastoma. Researcher noted that the median progression-free time for the tumor to begin growing again after treatment lengthened to 25.3 months instead of the typical eight months observed in patients given the standard treatment.
University of North Carolina Lineberger Comprehensive Cancer Center researchers and collaborators have mapped genetic changes that help drive an aggressive tumor as it develops in the brain – helping to lay the foundation for targeted treatment of the disease.
Researchers have discovered that an antibody currently being evaluated in an early clinical trial against advanced adult non–central nervous system solid tumors effectively shrinks malignant masses in mouse models of different pediatric brain cancers.
In an exclusive interview with Bioscience Technology, Sredni said that after so many years in the field, she has “never felt so close” to finding a better treatment for atypical teratoid/rhabdoid tumors (AT/RT) —and the powerful gene-editing tool CRISPR/Cas9 helped her get there.
Study investigated the spatial distributions of motor representations in terms of tumor-induced brain plasticity by analyzing navigated transcranial magnetic stimulation (nTMS) motor maps.
Officials said the effort seeks to demonstrate feasibility and safety in eliminating tumors located in the central part of the brain in patients ranging in age from 8 to 22. Researchers maintain that if untreated, the tumors often cause seizures, cognitive delays or other complications as they grow.
Over the years, NBTS has given more than $35 million to brain tumor research projects. The impact this funding has made in advancing the neuro-oncology field closer to better treatments and ultimately a cure.
Tools like Gamma Knife™ (stereotactic radiosurgery) can be used to precisely target tumors in the brain. In many cases where the Gamma Knife treatment option is utilized, brain tumors are successfully treated during one minimally invasive, out-patient appointment.
Researchers at Baylor College of Medicine, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor, Texas Children’s Hospital and Houston Methodist are investigating a new treatment option using modified T cells with anti-tumor properties with the goal of improving outcomes for patients with glioblastoma.
INSIGHTEC congratulates Nicklaus Children's Hospital, part of the Miami Children's Health System, for performing the first focused ultrasound procedure on a 21-year old patient suffering seizures associated with a benign hypothalamic hamartoma brain tumor.
Matthew Hunt performed the first laser ablation surgery at the University of Minnesota last month. Using robot-controlled lasers to fry cancerous tumors inside the brain has become a focus for University of Minnesota surgeons. Matthew Hunt, a neurosurgeon and professor at the University who performed the laser ablation, said the operation is a noninvasive method to treat tumors in parts of the brain that are hard to reach.
Scientists have successfully used the brains of these tropical grasshoppers as a testbed for a new type of drug delivery, one that could see life-saving medicines carried directly to the brain by way of a simple sniff.
Atypical teratoid/rhabdoid tumors (AT/RT) are a particularly aggressive type of brain tumor that typically occur in infants and are highly resistant to therapy. Scientists detailed findings that reveal a protein kinase called Polo-like kinase 4 (PLK4) is increased in AT/RT.
An experimental vaccine therapy shows promise in treating people with deadly glioblastoma brain cancer, researchers behind a small, preliminary study report.
A futuristic new device is helping some patients with brain cancer.
The "Optune" is comprised of arrays of electrodes which are placed on patients' heads to provide alternating electric fields. The electric fields make it hard or even impossible for cancer cells to reproduce.
Our data strongly suggest that exploiting the DNA repair deficiency in IDH-mutant tumors, rather than inhibiting the function of the mutant IDH proteins, likely will be a better strategy for treating brain tumors with these specific mutations, a devastating disease with an urgent need for better therapies - See more at: http://www.targetedonc.com/news/exploiting-dna-repair-deficiency-in-idhmutant-brain-tumors-likely-an-improved-treatment-strategy#sthash.3J0gVrRi.dpuf
Tumor-treating fields (TTFields) are a relatively new form of cancer treatment that send mild electrical fields through the scalp in an effort to block cell division. New results from a clinical trial have found that it significantly improves survival rates in brain cancer patients.
The two-year survival rate increased to 43% from 30% in patients treated with Optune plus chemo compared to chemo alone. The five-year survival increased to 13% from 5%. The company says these are the best results reported for newly diagnosed GBM patients in a late-stage study.
It sounds like science fiction, but a cap-like device that makes electric fields to fight cancer improved survival for the first time in more than a decade for people with deadly brain tumors, final results of a large study suggest.
Mutations of the isocitrate dehydrogenase (IDH) protein help the cancerous version of a brain tumor known as a glioma evade therapies that involve revving up the immune system, a study indicates. Another important finding was that inhibiting IDH mutations improved the effectiveness of an anti-glioma vaccine in mice.
Study identifies flaws in cancer cell metabolism that make high-dose vitamin C toxic to tumor cells
The National Brain Tumor Society (NBTS) announced the launch of a new brain-tumor clinical trial finder to engage patients in new research and ease the process of finding clinical trials.
Ziopharm Oncology Inc received positive guidance from the FDA for its brain cancer drug, Ad-RTS-hIL-12, plus orally administered veledimex (V)
Genetic changes and variants linked to the development of brain and ovarian cancers have been discovered in two new studies. This significant development offers researchers the chance to understand more about how these cancers develop and how they may one day be treated, or even prevented.
The event served as a way for clinics to share their most recent advancements and successes in stem cell therapy clinical trials, and even hear directly from patients who benefited from some of the trials.
Based on recent information on the mechanisms of chemotherapy, a team of researchers developed a new clinical approach to increase the efficiency of treatment in glioblastomas that increased the median survival to 22 months.
New tool will make it easier for brain tumor patients to find up-to-date information on clinical trials, enabling patients to better engage with medical research and make more informed decisions about their own treatment options in the era of precision medicine
The biotech firm Tocagen Inc. plans an Initial Public Offering to finance ongoing clinical trials of a technique that uses a weaponized virus to help the body’s immune system battle a common and deadly type of brain cancer.
The landscape for the treatment of brain cancer is improving, with researchers and patient advocates hoping the surge in clinical studies will pave the way for new approaches and drug combinations to treat these tumors.
When you hear the word Salmonella, you probably think about food poisoning rather than fighting brain cancer. However, one strain of the notorious bacterium may be able to do both.
Five types of pediatric brain cancer were safely and effectively treated in mice by an antibody that causes immune cells to engulf and eat tumors without hurting healthy brain cells, according to a new study by researchers at the Stanford University School of Medicine.
Cedars-Sinai investigators have identified a stem cell-regulating gene that affects tumor growth in patients with brain cancer and can strongly influence survival rates of patients. The findings could move physicians closer to their goal of better predicting the prognosis of patients with brain tumors and developing more personalized treatments for them.
It’s in its early stages, but Dr. Yaron Moshel is overseeing a promising drug trial called Toca 5, trying to prolong the lives of brain tumor patients.
Investigators have identified a stem cell-regulating gene that affects tumor growth in patients with brain cancer and can strongly influence survival rates of patients. The findings could move physicians closer to their goal of better predicting the prognosis of patients with brain tumors and developing more personalized treatments for them.
In the past few years oncologists have found that treating patients with only one drug is ineffective and often leads to relapse. One of the reasons might be that very few tumors are made up of only one kind of cell, which makes decisions about therapy extremely complex.
Modernizing diagnostic imaging and radiology services have the potential to extend MRI beyond anatomical imaging by providing information on physiology and cellular metabolism, thereby increasing the efficiency of diagnosis.
Researchers have revealed new insight into how the most deadly pediatric brain tumor, diffuse intrinsic pontine glioma (DIPG), may develop. They also have identified a compound that targets the "on" switch for cancer-promoting genes, which resulted in shrinking tumor size and increased survival in an animal model of DIPG.
A team of scientists from the UC Cancer Institute has discovered a variety of potential therapies that can treat cancers lacking essential tumor-suppression factors that occur naturally in the body.
"We found a new combination of therapeutics that could treat cancers that lack a protein called PTEN. PTEN is an important tumor suppressor, which means that it stops cell growth and division according to the needs of the body,"
In a study published in Nature Biomedical Engineering, the technique called Stimulated Raman Scattering microscopy opens up new possibilities to help surgeons determine the exact size of the cancerous cells and amount of tissue to be cut.
First use of graphene to detect cancer cells
With support from the Clinical and Translational Science Awards (CTSAs) at Duke and Carolina, Baldwin and Lo have teamed up to better understand the heterogeneity of brain cancer, using a new approach they’ve pioneered for growing and characterizing miniature human brain tumors in the lab. Ultimately, they hope to find new treatments or combinations of treatments to help more glioblastoma patients beat the odds.
A new class of therapies called SMAC mimetics could work in conjunction with immune checkpoint inhibitors to treat brain cancer patients, according to a study. SMAC mimetics block the activity of proteins that prevent cell death while sensitizing tumors to allow immune cells to attack them.
Researchers at the Yale School of Medicine’s Department of Therapeutic Radiology have identified a genetic defect in brain tumor cells that makes them sensitive to a class of drugs known as PARP inhibitors.
SRS microscopy has shown to quickly detect brain-tumor even in fresh and raw human tissue sample. The technique may serve as an effective alternative to traditional histologic procedures
Glioblastoma is the most deadly form of brain cancer in adults. Now an experimental therapy is helping some patients survive years beyond expectations.
Human skin can be morphed into genetically modified, cancer-killing brain stem cells, according to a new study.
In a new study, Yale Cancer Center researchers identified a novel genetic defect that prevents brain tumor cells from repairing damaged DNA. They found that the defect is highly sensitive to an existing FDA-approved drug used to treat ovarian cancer — a discovery that challenges current practice for treatment of brain tumors and other cancers with the same genetic defect, said the scientists.
In less than a year, researchers at UNC have made several advancements in the treatment of glioblastoma, and their work was published in the Feb. 1 issue of Science Translational Medicine. The research describes how human stem cells made from human skin cells can hunt down and kill brain cancer.
The pilot trials, approved by the U.S. Food and Drug Administration, both focus on the administration of chemotherapy agents directly into the fourth ventricle of the brain, the most common site for pediatric brain tumors and one that is difficult to access surgically.
A drug which may lead to the development of new brain cancer treatment might have been found. Researchers from the Peter O'Donnell Jr. Brain Institute and Harold C. Simmons Comprehensive Cancer Center reveal that a drug called mithramycin can stop the growth of aggressive brain cancer tumors.
Salmonella is typically associated with nothing better than severe digestive troubles, but in Discovery News’ new video, host Trace Dominguez explains how the bacteria could be modified to fight a type of aggressive brain cancer called glioblastoma.
An upcoming trial is testing the use of tumor treating fields (TTFields) for the grade 3 patient population. Currently, the device is only FDA approved for use in grade 4 brain tumors
Glioblastoma (GBM) is a tumor which is highly malignant or cancerous because the cells reproduce very quickly. It is difficult to treat because the tumors are composed of different types of cells. However, there are recent breakthroughs in medicine that may help patients be diagnosed with this deadly brain cancer.
Researchers have developed a new high-tech medical device for safer brain surgery. The so-called "smart needle" is a tiny imaging device encased in a brain biopsy needle. It can help surgeons avoid damaging fatal blood vessels or those which can cause major or permanent damage to the brain.